Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

How Does It Work for ITP? There is no cure for ITP. Its symptoms can vary from person to person, with some people not having any symptoms. Because ITP causes low platelets, the main side effects that ...

ITP affects about 5 people per 10,000. It can be associated with other conditions that are hematologic (leukemia) or ...

Whether you’ve been living with immune thrombocytopenia (ITP) for months or years, there’s no denying that the condition can ...

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

65.4% of hospitalized ITP inpatients did not have a bleeding episode or surgical procedure associated with their platelet transfusion. Platelet transfusions were not associated with improved clinical ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...

Medically reviewed by Doru Paul, MD Key Takeaways Low platelets can occur when your bone marrow doesn't make enough platelets ...

Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Up to 1,000 additional blood platelet donors are needed in the coming year to meet demand, as "there is no substitute for ...